Laboratory space available for lease Close to Monash University
Posted: 11 August 2023 Cartherics Pty Ltd built new laboratories in 2022/23 at Notting Hill Victoria just North of Monash University. The available area is a totally separate laboratory space of 155 m2 and 70 m2 open plan…
Soap made using ingredients from Country. Tested using Merck technology.
Posted: 11 August 2023 Merck travelled to the Northern Territory with the DeadlyScience team to pilot the first DeadlyLabs kit. It’s a project led by Indigenous Elders in the Robinson River region to share their knowledge, their ideas,…
Firebrick Phase 3 Trial Fully Recruited with 500 Subjects
Posted: 11 August 2023 Firebrick Pharma is pleased to announce that its Phase 3 trial of Nasodine Nasal Spray in the treatment for the common cold has successfully completed recruitment, with 500 subjects enrolled. “Subject to availability of…
EXO-OVARIAN CANCER SCREENING PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
Posted: 11 August 2023 INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, today announced results from an equivalence study to evaluate exosome-based biomarkers and performance of the EXO-OC test algorithm…
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
Posted: 11 August 2023 Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron…
SUCCESSFUL COMPLETION OF SECOND PLANNED DSMB REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL
Posted: 11 August 2023 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the independent Data Safety Monitoring Board (DSMB) has successfully concluded a second review of the ACTION3 phase…
Firebrick Covid-19 Trial Achieves Primary Endpoint
Posted: 7 August 2023 Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that its Phase 2 trial of Nasodine® Nasal Spray (“Nasodine”) in COVID-19 achieved its primary endpoint. The primary endpoint was the reduction in viral…
Adherium Accelerates Commercialisation with Largest US Allergy & Asthma Practice
Posted: 7 August 2023 Leading digital health company Adherium Limited (ASX:ADR) has signed a collaboration agreement with US–based Allergy Partners to transform asthma management for its more than 300,000 patients across 130 sites in 20 states. Allergy Partners…
AD-214 RETURNS TO CLINICAL STUDIES
Posted: 7 August 2023 AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products using its i-body platform provides an update on its lead fibrosis asset, AD-214. The first participants in the Company’s Phase I…
A mother’s diet can protect her grandchildren’s brains: genetic model study
Posted: 7 August 2023 Mothers who eat apples and herbs in early pregnancy could be protecting the brain health of their children and grandchildren, a Monash University study using genetic models has found. The discovery is part of…
3D digital technologies tackling mental injury prevention in health care
Posted: 7 August 2023 Designers have 3D-knitted bespoke hospital scrubs and 3D printed chill out pods for busy healthcare workers to improve their comfort and workplace mental health. The Safety Sensescaping project, funded by WorkSafe’s WorkWell Mental Health Improvement Fund,…
ACCENT Trial Recruitment Update
Posted: 7 August 2023 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to provide an update on progress in the ongoing Phase 1b/2a ACCENT clinical trial in first-line patients with advanced pancreatic cancer. The current…
